Myelodysplastic syndromes

Research output: Contribution to journalArticle

275 Citations (Scopus)

Abstract

There has been a remarkable explosion of knowledge into the molecular defects that underlie the acute and chronic leukemias, leading to the introduction of targeted therapies that can block key cellular events essential for the viability of the leukemic cell. Our understanding of the pathogenesis of the myelodysplastic syndromes (MDSs) has lagged behind, at least in part, because they represent a more heterogeneous group of disorders. The significant immunologic abnormalities described in this disease, coupled with the admixture of MDS stem or progenitor cells within the myriad types of dysplastic and normal cells in the bone marrow and peripheral blood, have made it difficult to molecularly characterize and model MDS. The recent availability of several, effective (ie, FDA-approved) therapies for MDS and newly described mouse models that mimic aspects of the human disease provide an opportune moment to try to leverage this new knowledge into a better understanding of and better therapies for MDS.

Original languageEnglish
Pages (from-to)4841-4851
Number of pages11
JournalBlood
Volume111
Issue number10
DOIs
StatePublished - May 15 2008
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Explosions
Bone
Blood
Cells
Availability
Stem Cells
Defects
Bone Marrow Cells
Cell Survival
Leukemia
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Myelodysplastic syndromes. / Nimer, Stephen D.

In: Blood, Vol. 111, No. 10, 15.05.2008, p. 4841-4851.

Research output: Contribution to journalArticle

Nimer, Stephen D. / Myelodysplastic syndromes. In: Blood. 2008 ; Vol. 111, No. 10. pp. 4841-4851.
@article{b129b33357fb4eaea1956481bd3122b0,
title = "Myelodysplastic syndromes",
abstract = "There has been a remarkable explosion of knowledge into the molecular defects that underlie the acute and chronic leukemias, leading to the introduction of targeted therapies that can block key cellular events essential for the viability of the leukemic cell. Our understanding of the pathogenesis of the myelodysplastic syndromes (MDSs) has lagged behind, at least in part, because they represent a more heterogeneous group of disorders. The significant immunologic abnormalities described in this disease, coupled with the admixture of MDS stem or progenitor cells within the myriad types of dysplastic and normal cells in the bone marrow and peripheral blood, have made it difficult to molecularly characterize and model MDS. The recent availability of several, effective (ie, FDA-approved) therapies for MDS and newly described mouse models that mimic aspects of the human disease provide an opportune moment to try to leverage this new knowledge into a better understanding of and better therapies for MDS.",
author = "Nimer, {Stephen D}",
year = "2008",
month = "5",
day = "15",
doi = "10.1182/blood-2007-08-078139",
language = "English",
volume = "111",
pages = "4841--4851",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Myelodysplastic syndromes

AU - Nimer, Stephen D

PY - 2008/5/15

Y1 - 2008/5/15

N2 - There has been a remarkable explosion of knowledge into the molecular defects that underlie the acute and chronic leukemias, leading to the introduction of targeted therapies that can block key cellular events essential for the viability of the leukemic cell. Our understanding of the pathogenesis of the myelodysplastic syndromes (MDSs) has lagged behind, at least in part, because they represent a more heterogeneous group of disorders. The significant immunologic abnormalities described in this disease, coupled with the admixture of MDS stem or progenitor cells within the myriad types of dysplastic and normal cells in the bone marrow and peripheral blood, have made it difficult to molecularly characterize and model MDS. The recent availability of several, effective (ie, FDA-approved) therapies for MDS and newly described mouse models that mimic aspects of the human disease provide an opportune moment to try to leverage this new knowledge into a better understanding of and better therapies for MDS.

AB - There has been a remarkable explosion of knowledge into the molecular defects that underlie the acute and chronic leukemias, leading to the introduction of targeted therapies that can block key cellular events essential for the viability of the leukemic cell. Our understanding of the pathogenesis of the myelodysplastic syndromes (MDSs) has lagged behind, at least in part, because they represent a more heterogeneous group of disorders. The significant immunologic abnormalities described in this disease, coupled with the admixture of MDS stem or progenitor cells within the myriad types of dysplastic and normal cells in the bone marrow and peripheral blood, have made it difficult to molecularly characterize and model MDS. The recent availability of several, effective (ie, FDA-approved) therapies for MDS and newly described mouse models that mimic aspects of the human disease provide an opportune moment to try to leverage this new knowledge into a better understanding of and better therapies for MDS.

UR - http://www.scopus.com/inward/record.url?scp=46749151451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46749151451&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-08-078139

DO - 10.1182/blood-2007-08-078139

M3 - Article

C2 - 18467609

AN - SCOPUS:46749151451

VL - 111

SP - 4841

EP - 4851

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -